SOURCE: Crucell N.V.

September 20, 2006 08:02 ET

Crucell to Present at UBS Global Life Sciences Conference, New York, September 28

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- September 20, 2006 --

Leiden, The Netherlands, September 20, 2006 - Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) has announced that its Chief Financial Officer, Leonard Kruimer, will present at the UBS Global Life Sciences Conference to be held next week (September 25-28) at the Grand Hyatt New York.

Mr Kruimer will present on Thursday, September 28 at 12:30 pm Eastern Time. A live webcast will be available during the presentation at and will be available for replay three hours afterwards.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. For more information, please visit

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V.                        For Crucell in the US:
Paul Vermeij                        Redington, Inc.
Director Investor Relations and     Thomas Redington
Corporate Communications            Tel. +1 212-926-1733
Tel. +31 (0)71 524 8718   

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information